Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity
- PMID: 16772343
- DOI: 10.1210/jc.2006-1006
Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity
Abstract
Context: RET/PTC rearrangements have been reported in papillary thyroid carcinomas with variable frequency in studies that used different detection methods.
Objective: Our objective was to determine the role of different detection methods and tumor genetic heterogeneity on RET/PTC detection.
Design: Sixty-five papillary carcinomas were analyzed for RET/PTC1 and RET/PTC3 using five detection methods: standard-sensitivity RT-PCR, high-sensitivity RT-PCR, real-time LightCycler RT-PCR, Southern blot analysis, and fluorescence in situ hybridization.
Results: RET/PTC rearrangements were detected by standard-sensitivity RT-PCR in 14 tumors. High-sensitivity RT-PCR detected RET/PTC in all of these and in 12 additional cases, where the levels of expression corresponded to one to five positive cells. Real-time LightCycler RT-PCR detected RET/PTC in 12 and Southern blot analysis in 11 tumors. By fluorescence in situ hybridization, 14 tumors were positive, including nine cases with 50-86% positive cells and five cases with 17-35% positive cells. Overall, nine (14%) tumors harbored clonal rearrangements, which were present in the majority of tumor cells and detected by all five methods. Five (8%) cases had subclonal rearrangements present in a smaller portion of tumor cells and detected by most methods. Twelve (18%) tumors had nonclonal RET/PTC that were detected only by high-sensitivity RT-PCR. No other mutations were found in tumors harboring clonal RET/PTC, whereas 60% of tumors with subclonal and 42% of tumors with nonclonal RET/PTC harbored additional mutations.
Conclusions: Our data suggest that broad variability in the reported prevalence of RET/PTC rearrangement is at least in part a result of the use of different detection methods and tumor genetic heterogeneity.
Similar articles
-
RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma.J Clin Endocrinol Metab. 2006 Jun;91(6):2414-23. doi: 10.1210/jc.2006-0240. Epub 2006 Apr 4. J Clin Endocrinol Metab. 2006. PMID: 16595592
-
Low prevalence of RET rearrangements (RET/PTC1, RET/PTC2, RET/PTC3, and ELKS-RET) in sporadic papillary thyroid carcinomas in Taiwan Chinese.Thyroid. 2005 Apr;15(4):326-35. doi: 10.1089/thy.2005.15.326. Thyroid. 2005. PMID: 15876154
-
[Molecular analysis of structural abnormalities in papillary thyroid carcinoma gene].Mol Biol (Mosk). 2004 Jul-Aug;38(4):642-53. Mol Biol (Mosk). 2004. PMID: 15456136 Russian.
-
Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.Cancer. 2005 Jun 1;103(11):2261-8. doi: 10.1002/cncr.21073. Cancer. 2005. PMID: 15880523 Review.
-
RET/PTC rearrangement in thyroid tumors.Endocr Pathol. 2002 Spring;13(1):3-16. doi: 10.1385/ep:13:1:03. Endocr Pathol. 2002. PMID: 12114746 Review.
Cited by
-
Tyrosine Kinase Inhibitors for Radioactive Iodine Refractory Differentiated Thyroid Cancer.Life (Basel). 2023 Dec 22;14(1):22. doi: 10.3390/life14010022. Life (Basel). 2023. PMID: 38255638 Free PMC article. Review.
-
RET-Altered Cancers-A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy Activity.Cancers (Basel). 2023 Aug 17;15(16):4146. doi: 10.3390/cancers15164146. Cancers (Basel). 2023. PMID: 37627175 Free PMC article. Review.
-
RET rearrangements are relevant to histopathologic subtypes and clinicopathological features in Thai papillary thyroid carcinoma patients.Pathol Oncol Res. 2023 Apr 28;29:1611138. doi: 10.3389/pore.2023.1611138. eCollection 2023. Pathol Oncol Res. 2023. PMID: 37188126 Free PMC article.
-
Approach to risk stratification for papillary thyroid carcinoma based on molecular profiling: institutional analysis.BJS Open. 2023 May 5;7(3):zrad029. doi: 10.1093/bjsopen/zrad029. BJS Open. 2023. PMID: 37146205 Free PMC article.
-
Case report: Dramatic response to pralsetinib in an elderly patient with advanced RET-fusion positive papillary thyroid carcinoma.Front Oncol. 2022 Dec 12;12:1042525. doi: 10.3389/fonc.2022.1042525. eCollection 2022. Front Oncol. 2022. PMID: 36578928 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
